To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Novel oral anticoagulants are similar to conventional treatment for venous thromboembolism

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
August 2013

Novel oral anticoagulants are similar to conventional treatment for venous thromboembolism

Vol: 2| Issue: 7| Number:315| ISSN#: 2564-2537
Study Type:Meta-analysis/Systematic Review
OE Level Evidence:1
Journal Level of Evidence:N/A

Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: Direct and adjusted indirect meta-analysis of randomised controlled trials

BMJ. 2012 Nov 13;345:e7498. doi: 10.1136/bmj.e7498

Contributing Authors:
BD Fox SR Kahn D Langleben MJ Eisenberg A Shimony

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

This meta-analysis and systematic review included 9 studies comparing novel oral anticoagulants (with or without initial treatment with heparin) to vitamin K antagonists (always with inital treatment with heparin) in patients with acute venous thromboembolism. From the 9 studies, 16 701 patients were assessed with regards to the efficacy of the drugs and 16 611 were evaluated on safety. Results in...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue